Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...

NIH researchers define diagnostic criteria for topical steroid withdrawal (TSW), distinguishing it from eczema.

Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...

Pfizer has gained FDA approval for Eucrisa, a new eczema treatment which could achieve peak annual sales of $2 billion a year. The drug is significant because it is the first non-steroidal therapy ...

While the IGNITE study evaluated rocatinlimab as monotherapy for 24 weeks, the SHUTTLE study evaluated the drug in combination with topical corticosteroids (TCS) and/or topical calcineurin ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Novartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Buried deep in the Swiss company’s Q2 results statement, the company said it had ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...